Paper published in Cardiovascular Revascularization Medicine shows innovative coronary artery implant is capable of moving with vessel, unlike conventional stents
Trial is evaluating DynamX Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology, allowing for the restoration of normal vessel functions essential to cardiovascular performance.
Elixir Medical Corporation: Elixir Medical Expands BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled trial (RCT) is expanding to centers in Belgium and Germany. The BIOADAPTOR RCT is evaluating the DynamX Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology.
The BIOADAPTOR RCT is a multicenter, randomized, single-blind study enrolling 444 patients from 30 centers in Europe and Japan treated with the DynamX Bioadaptor in a 1:1 randomization to Resolute Onyx, a leading drug-eluting stent (DES). The primary endpoint of the study is target lesion failure at one year. Secondary endpoints include measures of the implants ability to accommodate vessel growth from disease progression and restore artery pulsatility in an imaging subset, as well as other major cardiovasc